ArchiveOctober 2018

Advanced MS-The Missing Movie

In 2011 ProfG and Pharma dropped the baton (Stick in a relay race), but DrK picked it up and ran with it. Like Forest Gump he has been running ever since and Pharma has come back to help us finish the Race. I For the Past 6 Years DrK has been on a mission to get “treatment for all”. This journey has been filmed by one of the team, who has done a great job putting this short film...

JCV in Brazilian MS

Arq Neuropsiquiatr. 2018 Sep;76(9):588-591. doi: 10.1590/0004-282X20180083. Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis. Branco LP, Adoni T, Apostolos-Pereira SL, Brooks JBB, Correa EC, Damasceno CA, Eboni ACB, Fezer L, Gama PDD, Goncalves MVM, Gomes S, Grzesiuk AK, Mendes MF, Morales RR, Muniz A, Parolin MFK, Pimentel MLV, Ribeiro MC, Santos GACD, Sato...

Teriflunomide is not a high efficacy agent…predicted by B cells

We have been suggesting that the activity of drugs relate to their capacity to deplete memory B cells.  Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K. Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine. 2017;16:41-50. A student looking at table 1, said what happened to teriflunomide? I don’t know why I missed it. If we...

Information event for partners, family and friends of people newly diagnosed with MS

On Saturday 24th November we are working with Roche to deliver an information event for partners, family and friends of people newly diagnosed with MS.  It will be held in central London from 9.45am – 3:20pm and is free to attend with lunch and refreshments provided. If you are interested in coming along, please register here: ; On the day there will talks covering the science...

Are You Honest and Happy?

Are You Honest and Happy? Survey says Eijkholt M, Sparling A. Health, honesty and happiness: Authenticity and anonymity in social media participation of individuals with multiple sclerosis. Mult Scler Relat Disord. 2018 Sep 19;27:121-126 BACKGROUND:Multiple Sclerosis (MS) can impair social participation and lead to isolation. Online platforms could help to increase this participation...

Which is Best..I don’t know, they are much of a muchness

You asked which is best based on brain volume. The immune reconstitution agents (some people call this induction therapy..but it is a confusing terminology as it is used to describe the initial dosing schedule of oreclizumab) agents). These are alemtuzumab (Cohen et al. 2012, Coles et al. 2012) and cladribine (Giovannoni et al. 2010, Comi et al. 2013, de Stefano et al. 2018)) and possibly...

Too much vitamin D is not good for you

ProfG has been urging people to ensure that you are vitamin sufficient. He recommends the dose advised by the Vitamin D Council This will maintain bone health and maybe, just maybe it will impact on your MS. However some people have gone overboard and have found that to much of a good thing is bad. Here is the case of an individual who was taking 10 times the vitamin D council dose. Feige J...

The third course of Alemtuzumab

Yesterday some asked about the third cycle of alemtuzumab and if they had break through. If you live in England you may want to view this document It says  In May 2014 NICE published the Technology Appraisal (TA312): Alemtuzumab for treating relapsing-remitting multiple sclerosis and recommended that alemtuzumab is a treatment option, within its marketing authorisation (MA), for that...

NEPAD (knee pad) is a new way to view progression

We are all aware of NEDA but have you heard of NEPAD? We are all well aware of NEDA (pronounced Nee Dah), which is No Evidence of Disease Activity and relates to no gadolium enhancing/T2 lesions, no clinical relapses and no worsening of mobility. Then we can do NEDA-NFL, which is NEDA-4/5 and is NEDA-3 and no evidence of the production of neurofilaments as a marker of nerve damage. But as we...

Alemtuzumab 8y outcomes (ECTRIMS 2018)

  UK NHS England MS Treatment algorithm If you don’t know where you are going, all roads lead there; and in this case to alemtuzumab!  But can alemtuzumab puts its money where it’s mouth is?  In ECTRIMS we saw the publication of one their original clinical trial (CARE-MS II) follow up results after an 8 year period (see poster below). 56% (77% of the original...

Translate

Categories

Recent Posts

Recent Comments

Archives